Endocrine Oncology
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors that originate from endocrine cells located in e.g. the pancreas, the thyroid and in the gastrointestinal and respiratory tract. These cells have ability to secrete a variety of metabolically active products including peptide hormones and amines, which cause specific clinical symptoms. As the majority of NETs grow slowly they are commonly diagnosed late, which involves a higher risk for metastatic disease, and a worse prognosis. Our work aims to improve the diagnostics, and to develop new treatments of NETs. We are also engaged in clinical trials to evaluate new treatments.
Description of our research
The neuroendocrine oncology group is part of the Centre of Excellence for Neuroendocrine Tumors at Uppsala University and Uppsala University Hospital, one of the world leading centers for diagnosis and treatment of neuroendocrine tumors. We are also part of U-CAN an initiative to build a biobank of blood and tumor samples from patients with different sorts of cancer. Our large collections of tumor samples and clinical data are of great importance for the different lines of research that we pursue.
The research focuses on tumors derived from the small intestine, and studies e.g. the genetics of sporadic and familial NETs. In other projects the expression and clinical impact of neuroendocrine markers in neuroblastomas, breast cancer and small intestinal NETs are studied. Through the Nordic collaboration several projects directed towards neuroendocrine carcinomas are performed.
Group members
Publications
Part of ESMO Open, 2024
- DOI for Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers
- Download full text (pdf) of Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers
Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors
Part of Upsala Journal of Medical Sciences, 2024
Part of ESMO Open, 2024
- DOI for Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up5
- Download full text (pdf) of Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up5
Part of Journal of neuroendocrinology, 2024
- DOI for Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients
- Download full text (pdf) of Hypoalbuminemia, but not derived neutrophil to lymphocyte ratio (dNLR), predicts overall survival in neuroendocrine tumours undergoing peptide receptor radionuclide therapy: A retrospective, cohort study of 557 patients
Part of BMC Cancer, 2023
- DOI for Activity and safety of KEES-an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
- Download full text (pdf) of Activity and safety of KEES-an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer
Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms.
Part of Acta Oncologica, p. 431-437, 2023
Overall Survival in Patients with Stage IV Pan-NET Eligible for Liver Transplantation
Part of World Journal of Surgery, p. 340-347, 2023
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort
Part of Endocrine-Related Cancer, 2023
Part of Journal of neuroendocrinology, 2023
Part of Journal of neuroendocrinology, 2022
Loss of Y in leukocytes as a risk factor for critical COVID-19 in men
Part of Genome Medicine, 2022
Part of Neuroendocrinology, p. 298-309, 2022
Part of Annals of Surgery Open, 2022
- DOI for Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study
- Download full text (pdf) of Benefit of Primary Tumor Resection in Stage IV, Grade 1 and 2, Pancreatic Neuroendocrine Tumors: A Propensity-Score Matched Cohort Study
Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors
Part of Endocrine Connections, 2022
Part of PLOS ONE, 2022
- DOI for Central nervous system hemangioblastomas in von Hippel-Lindau disease: Total growth rate and risk of developing new lesions not associated with circulating VEGF levels
- Download full text (pdf) of Central nervous system hemangioblastomas in von Hippel-Lindau disease: Total growth rate and risk of developing new lesions not associated with circulating VEGF levels
Systemic treatment in patients with malignant pleural mesothelioma - real life experience
Part of BMC Cancer, 2022
Taxane-induced pain in breast cancer patients as perceived by nurses
Part of Acta Oncologica, p. 412-418, 2021
Part of Journal of Gastrointestinal Cancer, p. 212-221, 2021
- DOI for Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
- Download full text (pdf) of Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
Part of Neuroendocrinology, p. 883-894, 2021
Part of Neuroendocrinology, p. 330-343, 2021
- DOI for 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
- Download full text (pdf) of 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated With Chemotherapy: Analysis of Outcome, Safety and Their Determinants
Part of Journal of neuroendocrinology, 2021
Part of BJS Open, 2021
A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors
Part of Neuroendocrinology, p. 840-849, 2021
Part of Journal of neuroendocrinology, 2021
Part of Endocrine, p. 893-904, 2021
- DOI for Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
- Download full text (pdf) of Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumours grade 2
Part of Journal of neuroendocrinology, 2021
Part of Acta Oncologica, p. 931-941, 2021
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3
Part of PLOS ONE, 2020
Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3
Part of Scientific Reports, 2020
High-grade progression confers poor survival in pancreatic neuroendocrine tumors
Part of Neuroendocrinology, p. 891-898, 2020
Part of Neuroendocrinology, p. 217-224, 2020
Part of BMC Gastroenterology, 2020
Multiple hormone secretion may indicate worse prognosis in patients with ectopic Cushing's syndrome
Part of Hormones, p. 351-360, 2020
Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms
Part of Neuroendocrinology, p. 7-17, 2019
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
Part of Neuroendocrinology, p. 18-25, 2019
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
Part of Endocrine-Related Cancer, p. 227-239, 2019
Part of Journal of Pediatric Surgery, p. 1253-1256, 2019
Part of Endocrine pathology, p. 173-179, 2019
Part of INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY, 2019
Unmet Needs in Functional and Nonfunctional pancreatic neuroendocrine neoplasms
Part of Neuroendocrinology, p. 26-36, 2019
Colorectal Neuroendocrine Neoplasms - areas of unmet need
Part of Neuroendocrinology, p. 45-53, 2019
Unmet Needs in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms (WHO G3)
Part of Neuroendocrinology, p. 54-62, 2019
Unmet Needs in Appendiceal Neuroendocrine Neoplasms
Part of Neuroendocrinology, p. 37-44, 2019
Favorable Outcome in Patients with Pheochromocytoma and Paraganglioma Treated with 177Lu-DOTATATE.
Part of Cancers, 2019
Part of Neuroendocrinology, p. 184-184, 2018
Part of Medical Oncology, 2018
- DOI for Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
- Download full text (pdf) of Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Part of Cancers, 2018
Part of Neuroendocrinology, p. 152-152, 2018
Part of JAMA Oncology, p. 183-189, 2018
Part of Neuroendocrinology, p. 224-224, 2018